Examining the effects of brachytherapy on gynecological cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study analyzes the outcomes of brachytherapy in female patients diagnosed with various gynecological cancers, including cervical, endometrial, vulvar, and vaginal cancers. By reviewing historical patient data, the study aims to identify patterns and effectiveness of brachytherapy as a treatment option. The research will focus on patients aged 18 to 80 who have undergone this specific treatment, providing insights into its impact on cancer management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 - 80 female
* Underwent brachytherapy
* With gynecological cancer

Exclusion Criteria:

* Refusal to enter this trial

Where it's running

• Zhejiang Cancer Hospital
  Hangzhou, Zhejiang, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reiki therapy to help patients with gynecological cancers undergoing brachytherapy

  This study tests if Reiki therapy can help reduce anxiety, pain, and depression in women with gynecological cancers who are about to start brachytherapy.

  Recruiting Phase 2 University of Utah · Salt Lake City, Utah · NCT05979610

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Using Belzutifan to treat recurrent clear cell ovarian carcinoma

  This study is testing if a new targeted therapy called Belzutifan can help people with recurrent clear cell ovarian cancer feel better and manage their disease.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06677190

• Evaluating LY4170156 for advanced solid tumors

  This study is testing a new drug called LY4170156 to see if it is safe and effective for people with advanced solid tumors like ovarian and lung cancers.

  Recruiting at 24 sites Phase 1 Eli Lilly and Company · Scottsdale, Arizona and 24 other locations · NCT06400472

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.